<DOC>
	<DOCNO>NCT00040586</DOCNO>
	<brief_summary>The monoclonal antibody J591 investigate therapy patient prostate cancer , combination recombinant interleukin-2 ( Proleukin , Aldesleukin ) . The study open-label , non-randomized phase II study patient document hormone refractory prostate cancer .</brief_summary>
	<brief_title>Phase II Trial Monoclonal Antibody ( J591 ) Combination With Low-Dose Subcutaneous Interleukin-2</brief_title>
	<detailed_description>In Phase II , open label study , patient receive daily low-dose subcutaneous rIL-2 ( 1.2 x 10^6 IU/m^2/day ) continuously begin day 1 . Patients receive 3 week IL-2 , day 22 receive monoclonal antibody huJ591 via I.V . ( 25mg/m^2 ) 3 consecutive week . Il-2 continue 2 additional week total 8 week . The 8 week regimen constitute 1 cycle therapy . Patients respond therapy stable disease eligible additional cycle therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Eligibility Criteria : Histologic diagnosis ( recent remote ) prostate adenocarcinoma Metastatic recurrent carcinoma prostate define abnormal CT MRI and/or abnormal bone scan and/or rise PSA . Rising PSA 3 serial determination period &gt; equal 2 week . PSA &gt; equal 1.0 time entry . If patient treat LHRH analog drug : a. must maintain duration study b. must terminate &gt; equal 10 week prior entry ( 28 day depot preparation ) 24 week ( 3 month depot preparation ) . Prior cytotoxic chemotherapy and/or radiation therapy within 4 week entry . History CNS metastasis , and/or history seizure and/or stroke . Lab value : ANC &lt; 1500/mm3 ; platelet count &lt; 100,000/mm3 ; serum creatinine &gt; 2.0 ; SGOT &gt; 2 x normal ; bilirubin ( total ) &gt; 1.5 ; serum calcium &gt; equal 11.5 . Active serious infection control antibiotic . Active angina pectoris NYHA Class IIIIV . Karnofsky Performance Status &lt; 60 . Life Expectancy &lt; 3 month . Age &lt; 21y . Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study . Untreated thyroid disease , exception treat stable hyperthyroidism hypothyroidism least 4 week prior entry .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>hormone-refractory</keyword>
</DOC>